Immuno-PET
PET scans built from radiolabelled antibodies or their fragments, to see any protein an antibody can reach, including immune cells inside tumours.
Covers 89Zr-antibody imaging of ADC targets and T-cell imaging with 89Zr-crefmirlimab berdoxam (CD8 minibody) and 18F-AraG (activated T cells). CD8 PET is in phase 2/3 as a pharmacodynamic and predictive biomarker for checkpoint inhibitors.
How it works
Long-lived positron emitters (89Zr, 64Cu) chelated to antibodies, minibodies, or nanobodies.
- Images target and immune infiltrate non-invasively
- Any antibody can be turned into a tracer
- Slow kinetics for full antibodies
- Cost of 89Zr
Latest papers
topQuery for this technology: (TITLE:"immuno-PET" OR ABSTRACT:"immuno-PET" OR TITLE:"immunoPET" OR ABSTRACT:"immunoPET" OR TITLE:"CD8 PET" OR ABSTRACT:"CD8 PET" OR TITLE:"89Zr-labeled antibody" OR ABSTRACT:"89Zr-labeled antibody"). Results are unfiltered search hits about Immuno-PET, not a curated reading list.
Pages like this
not linked directly; found by shared links- PairingTROP2 PET → TROP2 ADC selection
Shares TROP2 PET to choose and sequence TROP2 ADCs, Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET, TROP2 PET, TROP2.
- PersonShaoli Song
- PersonTasuku Honjo
Shares PD-L1, No one can predict who responds to immunotherapy, PD-1, Melanoma.
- IdeaUse a blood test at six weeks to decide whether to keep going
Shares CD8 PET to stop or switch immunotherapy early, No one can predict who responds to immunotherapy, Melanoma, Non-small-cell lung cancer.
- TrialKEYNOTE-024 & KEYNOTE-189
Shares PD-L1, No one can predict who responds to immunotherapy, PD-1, Non-small-cell lung cancer.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares PD-L1, PD-1, Melanoma, Non-small-cell lung cancer.
- IdeaAlpha radioligands after ADC failure
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares PD-L1, PD-1, Melanoma, Non-small-cell lung cancer.